After Oppenheimer and H.C. Wainwright gave Vascular Biogenics (NASDAQ: VBLT) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Geulah Livshits reiterated a Buy rating on Vascular Biogenics today and set a price target of $5.00. The company’s shares closed last Tuesday at $2.05.
According to TipRanks.com, Livshits is a top 100 analyst with an average return of 77.1% and a 72.1% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and Intellia Therapeutics.
Vascular Biogenics has an analyst consensus of Strong Buy, with a price target consensus of $5.00, which is a 133.6% upside from current levels. In a report issued on March 25, Oppenheimer also maintained a Buy rating on the stock with a $5.00 price target.
The company has a one-year high of $3.17 and a one-year low of $1.01. Currently, Vascular Biogenics has an average volume of 1.06M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi’in, Israel.